Marshall Wace, LLP Pharvaris N.V. Transaction History
Marshall Wace, LLP
- $63.3 Billion
- Q1 2024
A detailed history of Marshall Wace, LLP transactions in Pharvaris N.V. stock. As of the latest transaction made, Marshall Wace, LLP holds 58,169 shares of PHVS stock, worth $980,147. This represents 0.0% of its overall portfolio holdings.
Number of Shares
58,169
Previous 60,124
3.25%
Holding current value
$980,147
Previous $1.69 Million
20.28%
% of portfolio
0.0%
Previous 0.0%
Shares
2 transactions
Others Institutions Holding PHVS
# of Institutions
35Shares Held
37.2MCall Options Held
0Put Options Held
0-
General Atlantic LLC New York, NY7.53MShares$127 Million4.07% of portfolio
-
Ven Bio Partners LLC San Francisco, CA4.29MShares$72.3 Million38.74% of portfolio
-
Foresite Capital Management Iv, LLC Larkspur, CA4.04MShares$68.1 Million47.16% of portfolio
-
Viking Global Investors LP3.65MShares$61.6 Million0.32% of portfolio
-
Vr Adviser, LLC New York, NY3.4MShares$57.2 Million6.74% of portfolio
About Pharvaris N.V.
- Ticker PHVS
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 33,766,000
- Market Cap $569M
- Description
- Pharvaris N.V., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases. The company develops PHA121, a small molecule bradykinin B2-receptor antagonist that is in Phase II clinical trial for the treatment of hereditary angioedema (HAE). It also develops PHVS416, an on-demand, r...